Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...

The recall, according to a news release published Wednesday, involves Northwest Naturals' Feline Turkey Recipe raw frozen pet ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Experts recommend 5 peptide-based medications for weight loss, such as liraglutide and semaglutide. They require medical ...

Critically, Lilly's Zepbound is a molecule called tirzepatide, and its ease of manufacturing is approximately equal to that ...